Microbot Medical Inc.
Microbot Medical develops robotic medical devices for minimally invasive endovascular procedures. Its main product is the LIBERTY® Endovascular Robotic Surgical System, a compact, single-use system designed for remote maneuvering of guidewires and catheters within blood vessels, currently focused on peripheral procedures. The FDA-cleared system is available through a limited market release in selected U.S. regions, and Microbot has established U.S. sales, marketing and distribution infrastructure. The company also holds NovaCross® technology for intraluminal revascularization devices. Microbot makes money through sales of its medical products. It relies on third parties to manufacture product candidates and commercial products. Its research and development work is conducted by employees and consultants in Israel, with support from academic and industry partners. Microbot Medical is headquartered in Hingham, Massachusetts.
No enriched coverage for $MBOT in the last 7 days.
No SEC Form 4 filings for $MBOT in the last 30 days.
See all $MBOT insider activity →Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion HINGHAM, Mass., November 5, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovasc
Microbot Medical (MBOT) received its first order for the LIBERTY Endovascular Robotic System from ELMNT IR, a California-based Office-Based Laboratory. The order is for up to a 12-month supply. ELMNT IR cited LIBERTY's compact design, efficient workflow, and lack of upfront costs as advantages. Microbot Medical views Office-Based Laboratories as a growing market for LIBERTY, expecting increased peripheral vascular procedures to drive revenue.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The
Recent MBOT coverage spans financial news, earnings and technology.
The new patent bolsters Microbot's IP moat and may support future regulatory clearances and market expansion, but the immediate pricing effect is likely modest.
The contract adds incremental revenue and validates market demand for the LIBERTY system.
First OBL customer signals market acceptance and geographic expansion, likely boosting investor sentiment.
New coverage could add upside.
Analyst upgrade and strong quarterly revenue growth could drive buying interest.
AlphAI scores every news story that mentions MBOT with an AI model for sentiment and relevance, and aggregates insider trades from Microbot Medical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion HINGHAM, Mass., November 5, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovasc
Microbot Medical (MBOT) received its first order for the LIBERTY Endovascular Robotic System from ELMNT IR, a California-based Office-Based Laboratory. The order is for up to a 12-month supply. ELMNT IR cited LIBERTY's compact design, efficient workflow, and lack of upfront costs as advantages. Microbot Medical views Office-Based Laboratories as a growing market for LIBERTY, expecting increased peripheral vascular procedures to drive revenue.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The
Analysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.
Citizens initiated coverage on Microbot Medical (MBOT) with an Outperform rating and a $2.50 price target, citing early commercialization of its LIBERTY robotic system. The company has $70M in cash and no debt, but faces execution risks. MBOT stock is near its 52-week low at $0.94. Q2 2026 revenue grew 100% YoY to $241K, but net loss widened to $5.6M. H.C. Wainwright maintained its Buy rating and $12.00 target.
H.C. Wainwright maintained a $12 price target for Microbot Medical (MBOT) after new patent approvals in the U.S., Japan, China, and Canada. The stock is near its 52-week low at $0.95. Q2 2026 revenue grew 100% to $241,000, but net loss widened to $5.6 million. The company signed a distribution deal in Israel and aims for European market entry.
Microbot Medical (MBOT) received patents in the U.S., Japan, China, and Canada for its LIBERTY Endovascular Robotic System. The company now has 44 issued patents and 49 pending applications. These approvals support its strategy for market entry into the EU and other regions, with the company pursuing a CE Mark for international expansion. The LIBERTY system is FDA-cleared and designed to reduce radiation exposure and physical strain in vascular procedures.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical ® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international market
Microbot Medical (MBOT) signed a 3-year exclusive deal with Medtechnica to distribute its LIBERTY system in Israel. The company received regulatory approval in May 2026 and expects initial orders in Q4 2026. This deal supports Microbot's international expansion and scaling plans.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical ® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Med
